People with relapsing-remitting multiple sclerosis (RRMS) who don’t use disease-modifying therapies (DMTs) are more likely to have been misdiagnosed previously, and to have poorer relationships with their healthcare providers, the results of a new survey suggest.
The survey, titled “Multiple Sclerosis In America 2019,” was conducted by Health Union, a company that’s created online communities for people with chronic conditions.
A total of 6,034 people responded to the survey between April 2 and June 24, 2019 — 5,911 MS patients, and 123 caregivers. Of the patients, about two-thirds had RRMS, which is the most common type of multiple sclerosis (MS).
Of the respondents with RRMS, 78% were taking a DMT — therapies aimed at slowing the natural course of MS. A further 16% had previously used a DMT but were no longer using one, and 6% had never used a DMT.
Among respondents who had never used a DMT, the most common reason, reported by 45%, for not using one was concern for side effects. Confidence in their current treatment, financial concerns, and a lack of recommendation from their current healthcare provider were also frequent reasons given for not using a DMT.
Respondents who were and weren’t taking DMTs were compared in order to better understand other factors that might lead a patient not to take a DMT.
“People with relapsing forms of MS who don’t use DMTs represent a small portion of the community, but it is so important to understand the unmet needs and nuances of their patient journeys,” Tim Armand, co-founder and president of Health Union, said in a news release.
Results showed that people who do not take DMTs were more likely to have been initially misdiagnosed, and to have been diagnosed more recently (less than two years ago). They were also less likely to have experienced symptoms before age 20.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?